2028 Biopharma Prescription 
pharmaphorum
JUNE 27, 2022
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Representative Training
JANUARY 29, 2025
While biologics only account for 2% of overall prescriptions, they contribute to 37% of net drug spending [1]. The global biosimilars market is projected to grow beyond $68 billion by 2028, as more biologic patents are set to expire and generic manufacturers are expected to enter and evolve the market with their business practices. [4]
Clarivate
MAY 13, 2024
Many insurers use similar networks for Medicaid and exchange plans, so shifting to an exchange plan is less likely to cause a lapse in coverage or abandonment of prescription drugs or maintenance medications that control chronic conditions.
Clarivate
AUGUST 20, 2024
Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.
Expert insights. Personalized for you.
111 
Let's personalize your content